A Phase 3 interventional study of Placebo and Sativex® in Palliative Care, Pain and Cancer, sponsored by Jazz Pharmaceuticals. Completed at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-05-03.
Sponsored by Jazz Pharmaceuticals · Phase 3, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing nabiximols in Pain — none open to participants now, none under way, none of them phase 3. nabiximols · Pain.
Among the 17 studies testing nabiximols in Pain, this one is the 10th largest by enrollment, is one of 6 that started in 2002, is one of 15 in phase 3, and was the 2nd registered.
10,069 studies on the registry are indexed under Pain; 1,650 are open to participants now.
Browse Pain studies →None of the 17 studies testing nabiximols in Pain is open now. The open studies under Pain, anywhere →
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 927 Pain studies recruiting now, 382 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 6 started in 2002.
This study's enrollment of 177 is above the median of 66 across 8,505 interventional studies indexed under Pain.
Median enrollment 246 across the 17 interventional studies. Of the 16 that completed or were terminated, 16 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 17 have an industry lead sponsor. The 3 most frequent:
Jazz Pharmaceuticals is the lead sponsor of 173 studies on the registry; 18 are open to participants now.
Of its 42 completed or terminated interventional studies of FDA-regulated products, 32 (76%) have results posted.
20 studies in Pain by Jazz Pharmaceuticals: none open now, none under way, none of them phase 3. Of 20 finished, 20 (100%) have results posted.
Among the 20 studies in Pain by Jazz Pharmaceuticals, this one is the 14th largest by enrollment, is one of 6 that started in 2002, is one of 18 in phase 3, and was the 6th registered.
Jazz Pharmaceuticals’s Pain studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 17 studies testing nabiximols in Pain, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Jazz Pharmaceuticals’s 20 in Pain:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether Sativex® and GW-2000-02 are effective in the management of subjects with intractable cancer-related pain.
This is a two week (two days baseline and two weeks treatment period), multicentre, double blind, randomised, placebo controlled, parallel group study to evaluate the efficacy of Sativex® and GW-2000-02 in subjects with cancer-related pain. Subjects are screened to determine eligibility and completed a two-day baseline period. Subjects then return to the centre for assessment, randomisation and dose introduction. All subjects are allowed to continue using all their current medications, provided that the dose remains stable throughout the study period. Their progress is reviewed after seven to 10 days and at the end of the study (day 14 to 20), or upon withdrawal. Subjects in this study are given the opportunity to be enrolled in an open label extension study (GWEXT0101).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo control
Drug: Placebo
Active treatment
Drug: Sativex®
Active treatment
Drug: THC Alone
Containing colourants and excipients. Subjects received study medication delivered in 100 µl actuations by a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three hour period and 48 actuations in 24 hours.
Also known as: GW-4000-01
Containing D9 tetrahydrocannabinol (THC), 27 mg/ml: cannabidiol (CBD), 25 mg/ml. Subjects received study medication delivered in 100 µl actuations by a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three hour period and 48 actuations (THC 130 mg:CBD 120 mg) in 24 hours.
Also known as: GW-1000-02
Containing THC, 27 mg/ml, as extract of Cannabis sativa L. Subjects received study medication delivered in 100 µl actuations by a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three hour period and 48 actuations (THC 130 mg) in 24 hours.
Also known as: GW-2000-02, THC
The Change in Mean Pain Numerical Rating Scale (NRS) Score From Baseline to the End of the Treatment.
The pain NRS was complete at the same time each day, i.e. bedtime in the evening. The patient was asked "on a scale of '0 to 10', please indicate the number that best describes your pain or average pain in the last 24 hours" where 0 = no pain and 10 = pain as bad as you can imagine. No pain relates to the time prior to the onset of pain due to cancer. A negative value indicates an improvement in pain score from baseline.
Time frame: 2 weeks: baseline - end of week 2 (last 3 days of treatment)
The Consumption of Escape Analgesic Medication.
Subjects recorded their use of escape medication each day on their diary card.
Time frame: 2 weeks: baseline - end of week 2 (last 3 days of treatment)
Sleep Disturbance 0-10 Numerical Rating Scale
The sleep disruption NRS was completed at the same time each day, i.e. bedtime in the evening. The patient was asked "on a scale of '0 to 10', please indicate how your pain disrupted your sleep last night?" where 0 = did not disrupt sleep and 10 = completely disrupted (unable to sleep at all). A negative value indicates an improvement in sleep disruption score from baseline.
Time frame: 2 weeks: baseline to end of week 2 (last 3 days of treatment)
Nausea 0-10 Numerical Rating Scale
The nausea NRS was completed at the same time each day, i.e. bedtime in the evening. The patient was asked "on a scale of '0 to 10', please indicate how sick you felt throughout the day?" where 0 = not sick at all and 10 = very sick. A negative value indicates an improvement in nausea score from baseline.
Time frame: 2 weeks; baseline - end of week 2 (last 3 days of treatment)
Memory 0-10 Numerical Rating Scale
The memory NRS was completed at the same time each day, i.e. bedtime in the evening. The patient was asked "on a scale of '0 to 10', please indicate how well you are able to remember what you have done in the past 24 hours?" where 0 = very well and 10 = not at all. A negative value indicates an improvement in memory score from baseline.
Time frame: 2 weeks: baseline - end of week 2 (last 3 days of treatment)
Appetite 0-10 Numerical Rating Scale
The appetite NRS was completed at the same time each day, i.e. bedtime in the evening. The patient was asked "on a scale of '0 to 10', please indicate how your appetite has been throughout the day?" where 0 = very good and 10 = very poor. A negative value indicates an improvement in appetite score from baseline.
Time frame: 2 weeks: baseline - end of week 2 (last 3 days of treatment)
Concentration 0-10 Numerical Rating Scale
The concentration NRS was completed at the same time each day, i.e. bedtime in the evening. The patient was asked "on a scale of '0 to 10', please indicate how well have you been able to concentrate throughout the day e.g. when reading a newspaper?" where 0 = very well and 10 = not at all. A negative value indicates an improvement in concentration score from baseline.
Time frame: 2 weeks: baseline - end of week 2 (last 3 days of treatment)
EORTC Quality of Life Questionnaire (EORTC-QLQC30)
Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30), a core cancer-specific questionnaire containing 30 items on patients' functioning, global quality of life, disease- and treatment related symptoms. Higher scores indicate a greater degree of symptoms, min.: 0, Max.: 100
Time frame: 2 weeks; baseline and end of treatment (2 weeks)
Brief Pain Inventory Short Form
The BPI-SF is a 14-item questionnaire that asks patients to rate pain over the prior week and the degree to which it interferes with activities on a 0 to 10 scale, where 0=no pain and 10=pain as bad as you can imagine. Severity is measured as worst pain, least pain, average pain, and pain right now. The severity composite score was calculated as the arithmetic mean of the four severity items(range 0-10). The minimum value is zero and maximum is 10. A higher score represents a poor outcome.
Time frame: End of 2 weeks
| Milestone | Sativex | THC Alone | Placebo |
|---|---|---|---|
| Started | 60 | 58 | 59 |
| Completed | 48 | 45 | 51 |
| Not completed | 12 | 13 | 8 |
The pain NRS was complete at the same time each day, i.e. bedtime in the evening. The patient was asked "on a scale of '0 to 10', please indicate the number that best describes your pain or average pain in the last 24 hours" where 0 = no pain and 10 = pain as bad as you can imagine. No pain relates to the time prior to the onset of pain due to cancer. A negative value indicates an improvement in pain score from baseline.
| units on a scale | Sativex | THC Alone | Placebo |
|---|---|---|---|
| The Change in Mean Pain Numerical Rating Scale (NRS) Score From Baseline to the End of the Treatment. | -1.32 ± 1.64 | -0.93 ± 1.15 | -0.73 ± 1.51 |
The sleep disruption NRS was completed at the same time each day, i.e. bedtime in the evening. The patient was asked "on a scale of '0 to 10', please indicate how your pain disrupted your sleep last night?" where 0 = did not disrupt sleep and 10 = completely disrupted (unable to sleep at all). A negative value indicates an improvement in sleep disruption score from baseline.
| units on a scale | Sativex | THC Alone | Placebo |
|---|---|---|---|
| Sleep Disturbance 0-10 Numerical Rating Scale | -0.59 ± 1.88 | -0.25 ± 2.33 | -0.21 ± 1.72 |
The nausea NRS was completed at the same time each day, i.e. bedtime in the evening. The patient was asked "on a scale of '0 to 10', please indicate how sick you felt throughout the day?" where 0 = not sick at all and 10 = very sick. A negative value indicates an improvement in nausea score from baseline.
| units on a scale | Sativex | THC Alone | Placebo |
|---|---|---|---|
| Nausea 0-10 Numerical Rating Scale | 0 ± 2.19 | 0.27 ± 1.83 | -0.16 ± 1.25 |
The memory NRS was completed at the same time each day, i.e. bedtime in the evening. The patient was asked "on a scale of '0 to 10', please indicate how well you are able to remember what you have done in the past 24 hours?" where 0 = very well and 10 = not at all. A negative value indicates an improvement in memory score from baseline.
| units on a scale | Sativex | THC Alone | Placebo |
|---|---|---|---|
| Memory 0-10 Numerical Rating Scale | 0.58 ± 2.06 | 0.57 ± 1.90 | 0 ± 1.35 |
The appetite NRS was completed at the same time each day, i.e. bedtime in the evening. The patient was asked "on a scale of '0 to 10', please indicate how your appetite has been throughout the day?" where 0 = very good and 10 = very poor. A negative value indicates an improvement in appetite score from baseline.
| units on a scale | Sativex | THC Alone | Placebo |
|---|---|---|---|
| Appetite 0-10 Numerical Rating Scale | 0.24 ± 2.29 | 0.18 ± 1.91 | -1.65 ± 1.94 |
The concentration NRS was completed at the same time each day, i.e. bedtime in the evening. The patient was asked "on a scale of '0 to 10', please indicate how well have you been able to concentrate throughout the day e.g. when reading a newspaper?" where 0 = very well and 10 = not at all. A negative value indicates an improvement in concentration score from baseline.
| units on a scale | Sativex | THC Alone | Placebo |
|---|---|---|---|
| Concentration 0-10 Numerical Rating Scale | 0.26 ± 1.66 | 0.22 ± 1.80 | -0.32 ± 1.39 |
Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30), a core cancer-specific questionnaire containing 30 items on patients' functioning, global quality of life, disease- and treatment related symptoms. Higher scores indicate a greater degree of symptoms, min.: 0, Max.: 100
| units on a scale | Sativex | THC Alone | Placebo |
|---|---|---|---|
| EORTC Quality of Life Questionnaire (EORTC-QLQC30) | 4.93 ± 17.51 | 3.57 ± 18.32 | 4.74 ± 18.50 |
The BPI-SF is a 14-item questionnaire that asks patients to rate pain over the prior week and the degree to which it interferes with activities on a 0 to 10 scale, where 0=no pain and 10=pain as bad as you can imagine. Severity is measured as worst pain, least pain, average pain, and pain right now. The severity composite score was calculated as the arithmetic mean of the four severity items(range 0-10). The minimum value is zero and maximum is 10. A higher score represents a poor outcome.
| units on a scale | Sativex | THC Alone | Placebo |
|---|---|---|---|
| Brief Pain Inventory Short Form | 0.2 ± 5.63 | -3.38 ± 6.43 | 0.41 ± 5.55 |
Subjects recorded their use of escape medication each day on their diary card.
| tablets per day | Sativex | THC Alone | Placebo |
|---|---|---|---|
| The Consumption of Escape Analgesic Medication. | 0.72 ± 0.821 | 0.88 ± 0.852 | 0.68 ± 0.662 |
Collected over All adverse events (AEs) occurring from the time of consent to post study follow up (14 - 20 days) were collected. All deaths and serious adverse events (SAEs) occurring within 28 days of the final dose of study medication were also collected.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sativex | — | 13/60 (21.7%) | 51/60 (85%) |
| THC Alone | — | 13/58 (22.4%) | 45/58 (77.6%) |
| Placebo | — | 7/59 (11.9%) | 44/59 (74.6%) |
| Event | Sativex | THC Alone | Placebo |
|---|---|---|---|
| Neoplasm progression nosNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 6/60 | 5/58 | 2/59 |
| Metastases to brainNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/60 | 2/58 | 0/59 |
| SomnolenceNervous system disorders | 1/60 | 2/58 | 1/59 |
| ConfusionPsychiatric disorders | 0/60 | 2/58 | 1/59 |
| Cardio-respiratory arrestCardiac disorders | 0/60 | 0/58 | 2/59 |
| Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/60 | 0/58 | 2/59 |
| Urinary retentionRenal and urinary disorders | 2/60 | 0/58 | 0/59 |
| Gastric ulcer haemorrhageGastrointestinal disorders | 0/60 | 1/58 | 0/59 |
| NauseaGastrointestinal disorders | 0/60 | 1/58 | 0/59 |
| Disease progression nosGeneral disorders | 1/60 | 1/58 | 0/59 |
| Event | Sativex | THC Alone | Placebo |
|---|---|---|---|
| SomnolenceNervous system disorders | 9/60 | 8/58 | 8/59 |
| DizzinessNervous system disorders | 7/60 | 7/58 | 3/59 |
| NauseaGastrointestinal disorders | 7/60 | 6/58 | 6/59 |
| ConstipationGastrointestinal disorders | 3/60 | 0/58 | 6/59 |
| Neoplasm progression NOSNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 6/60 | 5/58 | 3/59 |
| Oral painGeneral disorders | 0/60 | 5/58 | 3/59 |
| GlossodyniaGeneral disorders | 0/60 | 5/58 | 0/59 |
| Gamma-glutamyltransferase increasedInvestigations | 0/60 | 5/58 | 3/59 |
| VomitingGastrointestinal disorders | 5/60 | 4/58 | 4/59 |
| ConfusionPsychiatric disorders | 4/60 | 0/58 | 2/59 |
| Age, Categorical(Participants) | Sativex | THC Alone | Placebo | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 39 | 38 | 38 | 115 |
| >=65 years | 21 | 20 | 21 | 62 |
| Age, Continuous(years) | Sativex | THC Alone | Placebo | Total |
|---|---|---|---|---|
| Mean | 59.4 ± 12.08 | 61.3 ± 12.5 | 60.1 ± 12.31 | 60.2 ± 12.25 |
| Sex: Female, Male(Participants) | Sativex | THC Alone | Placebo | Total |
|---|---|---|---|---|
| Female | 27 | 28 | 27 | 82 |
| Male | 33 | 30 | 32 | 95 |
| Region of Enrollment(participants) | Sativex | THC Alone | Placebo | Total |
|---|---|---|---|---|
| United Kingdom | 22 | 18 | 21 | 61 |
| Belgium | 4 | 4 | 3 | 11 |
| Romania | 34 | 36 | 35 | 105 |
The record gives a start of Feb 2002, a primary completion of Feb 2004 and a completion of Mar 2004. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2012, 8 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Nabiximols · Dronabinol